このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

RHÖN-KLINIKUM 将来の成長

Future 基準チェック /16

RHÖN-KLINIKUMの収益は年間2.6%で減少すると予測されていますが、年間利益は年間7.2%で増加すると予想されています。EPS は年間6.8%で増加すると予想されています。

主要情報

7.2%

収益成長率

6.8%

EPS成長率

Healthcare 収益成長	20.8%
収益成長率	-2.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	10 May 2024

今後の成長に関する最新情報

Recent updates

RHÖN-KLINIKUM Aktiengesellschaft's (ETR:RHK) Business Is Trailing The Market But Its Shares Aren't

Jun 26

RHÖN-KLINIKUM (ETR:RHK) Seems To Use Debt Rather Sparingly

Apr 25

RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

Mar 02

Is RHÖN-KLINIKUM (ETR:RHK) Using Too Much Debt?

Dec 19

Here's Why RHÖN-KLINIKUM (ETR:RHK) Can Manage Its Debt Responsibly

Jul 13

There Are Reasons To Feel Uneasy About RHÖN-KLINIKUM's (ETR:RHK) Returns On Capital

Jun 15

These 4 Measures Indicate That RHÖN-KLINIKUM (ETR:RHK) Is Using Debt Reasonably Well

Sep 20

業績と収益の成長予測

XTRA:RHK - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,605	52	N/A	N/A	1
12/31/2025	1,566	47	N/A	N/A	1
12/31/2024	1,520	43	N/A	N/A	1
3/31/2024	1,767	43	N/A	N/A	N/A
12/31/2023	1,735	39	46	109	N/A
9/30/2023	1,706	32	N/A	N/A	N/A
6/30/2023	1,688	26	-36	18	N/A
3/31/2023	1,690	30	N/A	N/A	N/A
12/31/2022	1,661	25	2	60	N/A
9/30/2022	1,640	30	N/A	N/A	N/A
6/30/2022	1,628	32	-18	48	N/A
3/31/2022	1,602	28	N/A	N/A	N/A
12/31/2021	1,591	28	20	98	N/A
9/30/2021	1,557	15	N/A	N/A	N/A
6/30/2021	1,554	14	23	117	N/A
3/31/2021	1,549	7	N/A	N/A	N/A
12/31/2020	1,546	1	16	113	N/A
9/30/2020	1,537	8	20	113	N/A
6/30/2020	1,532	19	10	100	N/A
3/31/2020	1,513	31	-28	63	N/A
12/31/2019	1,481	43	-67	47	N/A
9/30/2019	1,436	40	-61	91	N/A
6/30/2019	1,413	52	-95	74	N/A
3/31/2019	1,394	47	-134	46	N/A
12/31/2018	1,390	49	-114	50	N/A
9/30/2018	1,411	55	-114	24	N/A
6/30/2018	1,385	36	-76	54	N/A
3/31/2018	1,374	37	-57	63	N/A
12/31/2017	1,362	35	N/A	80	N/A
9/30/2017	1,340	2	N/A	69	N/A
6/30/2017	1,330	4	N/A	87	N/A
3/31/2017	1,334	14	N/A	96	N/A
12/31/2016	1,319	56	N/A	109	N/A
9/30/2016	1,291	101	N/A	114	N/A
6/30/2016	1,276	105	N/A	101	N/A
3/31/2016	1,251	103	N/A	80	N/A
12/31/2015	1,240	85	N/A	67	N/A
9/30/2015	1,250	66	N/A	63	N/A
6/30/2015	1,248	62	N/A	54	N/A
3/31/2015	1,300	-138	N/A	55	N/A
12/31/2014	1,666	1,226	N/A	49	N/A
9/30/2014	2,171	1,245	N/A	67	N/A
6/30/2014	2,661	1,250	N/A	153	N/A
3/31/2014	3,098	1,459	N/A	209	N/A
12/31/2013	3,223	87	N/A	210	N/A
9/30/2013	3,189	87	N/A	199	N/A
6/30/2013	3,167	90	N/A	171	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RHKの予測収益成長率 (年間7.2% ) は貯蓄率 ( 0.7% ) を上回っています。

収益対市場: RHKの収益 ( 7.2% ) German市場 ( 18.6% ) よりも低い成長が予測されています。

高成長収益: RHKの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: RHKの収益は今後 3 年間で減少すると予想されています (年間-2.6% )。

高い収益成長: RHKの収益は今後 3 年間で減少すると予測されています (年間-2.6% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RHKの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

RHÖN-KLINIKUM 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased to €15.00

Price target decreased to €16.50

Consensus EPS estimates fall to €0.23

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

Recent updates

RHÖN-KLINIKUM Aktiengesellschaft's (ETR:RHK) Business Is Trailing The Market But Its Shares Aren't

First quarter 2024 earnings released: EPS: €0.16 (vs €0.09 in 1Q 2023)

RHÖN-KLINIKUM (ETR:RHK) Seems To Use Debt Rather Sparingly

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: €0.58 (vs €0.38 in FY 2022)

RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 15%

Is RHÖN-KLINIKUM (ETR:RHK) Using Too Much Debt?

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2024 Results on Aug 08, 2024

Third quarter 2023 earnings released: EPS: €0.17 (vs €0.069 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.09 (vs €0.16 in 2Q 2022)

Here's Why RHÖN-KLINIKUM (ETR:RHK) Can Manage Its Debt Responsibly

There Are Reasons To Feel Uneasy About RHÖN-KLINIKUM's (ETR:RHK) Returns On Capital

Upcoming dividend of €0.15 per share at 1.2% yield

Full year 2022 earnings released: EPS: €0.38 (vs €0.42 in FY 2021)

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 30, 2023

Price target decreased to €15.00

These 4 Measures Indicate That RHÖN-KLINIKUM (ETR:RHK) Is Using Debt Reasonably Well

Capital Allocation Trends At RHÖN-KLINIKUM (ETR:RHK) Aren't Ideal

Second quarter 2022 earnings released: EPS: €0.16 (vs €0.10 in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to €16.50

Robust Earnings May Not Tell The Whole Story For RHÖN-KLINIKUM (ETR:RHK)

Third quarter 2021 earnings released: EPS €0.10 (vs €0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.10 (vs €0.003 in 2Q 2020)

Does RHÖN-KLINIKUM (ETR:RHK) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: EPS €0.02 (vs €0.066 loss in 1Q 2020)

Consensus EPS estimates fall to €0.23

Full year 2020 earnings released: EPS €0.02 (vs €0.65 in FY 2019)

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2021 Results on Aug 05, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: €15.50

New 90-day low: €16.10

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q4, 2020 Final Results on Mar 25, 2021

Third quarter 2020 earnings released: EPS €0.09

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

Medgate Holding AG acquired remaining 51% stake in Medgate Deutschland GmbH from RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK).

RHÃ–N-KLINIKUM Aktiengesellschaft to Report Nine Months, 2020 Results on Nov 06, 2020

New 90-day low: €15.98

New 90-day low - €16.96

Upcoming Dividend of €0.25 Per Share

Asklepios Kliniken GmbH & Co. KGaA completed the acquisition of additional 42.5% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from HCM SE, B. Braun Melsungen AG, Landeskrankenhilfe V.V.A.G, Asset Management Arm and others for approximately €510 million.

Asklepios Kliniken GmbH concluded the acquisition of additional 12.4% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from Eugen Münch and Ingeborg Münch.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘